logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

Possibilities of molecular biopsy in differential diagnosis of pulmonary arterial hypertension: case description and literature review

[Notes from practice]
Elena Dankovtseva; Natalya Osipova; Larisa Minushkina; Gleb Speshilov; Alexey Nikitin; Albert Galyavich; Krestina Remblevskaya; Dmitry Zateyschikov;

Precision studies of pulmonary arterial hypertension (PAH) have led to identification of the subgroup of pulmonary venoocclusive disease (PVOD). The article describes the clinical case of the hereditary form of PAH in a 53-year-old woman. Using next-generation sequencing we found biallelic mutations in the EIF2AK4 gene – c.C2965T variant in the heterozygous state resulting in the non-synonymous substitution in the position 989 of the protein (p.Arg989Trp) and the non-described variant c.859+1G>A in the exon 7 in the heterozygous state. Taking into consideration the genetic data, the diagnosis in this case was changed from idiopathic PAH to PVOD. So, implementation of molecular genetic methods in routine clinical examination of patients with PAH can greatly improve and speed up the diagnostic process.

Download

References:
1. Galie N., Humbert M., Vachiery J. L., Gibbs S., Lang I. [et al.] Group ESCSD: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016;37(1):67-119. https://doi.org/10.1093/eurheartj/ehv31
2. Chaisson N. F., Dodson M. W., Elliott C. G. Pulmonary capillary hemangiomatosis and pulmonary veno-occlusive disease. Clin. Chest. Med. 2016, 37(3):523-534. https://doi.org/10.1016/j.ccm.2016.04.014
3. Navas T. P., Palomino D. J., Tenorio C. J. A., Enguita V. A. B., Rodriguez R. J. J. [et al.] Variable expressivity of a founder mutation in the EIF2AK4 gene in hereditary pulmonary veno-occlusive disease and its impact on survival. Rev. Esp. Cardiol. (Engl. Ed.). 2018;71(2):86-94. https://doi.org/10.1016/j.rec.2017.03.034
4. Chen R., Im H., Snyder M. Whole-exome enrichment with the Roche NimbleGen SeqCap EZ Exome Library SR platform. Cold Spring Harb. Protoc. 2015;(7):634- 641. https://doi.org/10.1101/pdb.prot084855
5. van der Werf I. M., Kooy R. F., Vandeweyer G. A robust protocol to increase NimbleGen SeqCap EZ multiplexing capacity to 96 samples. PloS One. 2015;10(4):e0123872. https://doi.org/10.1371/journal.pone.0123872
6. Yang H., Zeng Q., Ma Y., Liu B., Chen Q. [et al.] Genetic analyses in a cohort of 191 pulmonary arterial hypertension patients. Respir. Res. 2018;19(1):87.
https://doi.org/10.1186/s12931-018-0789-9
7. Ogawa A., Takahashi Y., Matsubara H.: Clinical prediction score for identifying patients with pulmonary venoocclusive disease/pulmonary capillary hemangiomatosis. J. Cardiol. 2018;72(3):255-260. https://doi.org/10.1016/j.jjcc.2018.02.009
8. Matsushita K., Kanna M., Yazawa T., Shimizu S., Nitta M. [et al.] Long-term survivor with pulmonary veno-occlusive disease. Circulation. 2012;125(12):e503-e506. https://doi.org/10.1161/CIRCULATIONAHA.111.088450
9. Montani D., Lau E. M., Dorfmuller P., Girerd B., Jais X. [et al.] Pulmonary veno-occlusive disease. Eur. Respir. J. 2016;May47(5):1518-34. https://doi.org/10.1183/13993003.00026-2016
10. Lederer H., Muggli B., Speich R., Treder U., Stricker H. [et al.] Haemosiderin-laden sputum macrophages for diagnosis in pulmonary veno-occlusive disease. PloS One. 2014;9(12):e115219. https://doi.org/10.1371/journal.pone.0115219
11. Hadinnapola C., Bleda M., Haimel M., Screaton N., Swift A. [et al.] Consortium NB-RD, Idiopathic UKNCSo, Heritable PAH, Graf S, Morrell NW: Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of
patients diagnosed clinically with pulmonary arterial hypertension. Circulation. 2017;136(21):2022-2033. https://doi.org/10.1161/CIRCULATIONAHA.117.028351
12. Montani D., Lau E. M., Descatha A., Jais X., Savale L. [et al.] Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur. Respir. J. 2015;46(6):1721-1731. https://doi.org/10.1183/13993003.00814-2015
13. Chamorro F. C. I., Garces C. P., Perez M. R., Sanchez S. R. M., Ferrando S. C. [et al.] The first experience of pulmonary veno-occlusive disease treatment with
macitentan and sildenafil. Rev. Esp. Cardiol. (Engl. Ed.). 2017;70(5):396-397.
https://doi.org/10.1016/j.rec.2016.07.011 14. Montani D., Girerd B., Jais X., Levy M., Amar D. [et al.] Clinical phenotypes and outcomes of heritable and
sporadic pulmonary veno-occlusive disease: a populationbased study. Lancet Respir. Med. 2017 Feb;5(2):125- 134. https://doi.org/10.1016/S2213-2600(16)30438-6
15. Eyries M., Montani D., Girerd B., Perret C., Leroy A. [et al.] EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat. Genet. 2014;46(1):65-69. https://doi.org/10.1038/ng.2844
16. Tenorio J., Navas P., Barrios E., Fernandez L., Nevado J. [et al.] A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clin. Genet. 2015, 88(6):579-583. https://doi.org/10.1111/cge.12549
17. Best D. H., Sumner K. L., Austin E. D., Chung W. K., Brown L. M. [et al.] EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest. 2014;145(2):231- 236. https://doi.org/10.1378/chest.13-2366
18. Eichstaedt C. A., Song J., Benjamin N., Harutyunova S., Fischer C. [et al.] EIF2AK4 mutation as «second hit» in hereditary pulmonary arterial hypertension. Respir. Res. 2016; 17(1):141. https://doi.org/10.1186/s12931-016-0457-x
19. Liang L., Ma G., Chen K., Liu Y., Wu X. [et al.] EIF2AK4 mutation in pulmonary veno-occlusive disease: A case report and review of the literature. Medicine (Baltimore). 2016;95(39):e5030. https://doi.org/10.1097/MD.0000000000005030

Keywords: pulmonary arterial hypertension, pulmonary venoocclusive disease, EIF2AK4 gene mutations


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy